UK: Beakers And Bunsens: A Spotlight On The Treatment Of Rare Diseases

Last Updated: 28 February 2019
Article by Joseph Lenthall

Thursday 28 February 2019 is "Rare Disease Day". The day aims to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. The first Rare Disease Day was celebrated on the "rare" date of 29 February in 2009 and is celebrated on the last day of February every year.

Rare (or orphan) diseases are those diseases that affect only a tiny fraction of the population. In Europe, the disease or disorder is generally classified as rare if the disease affects fewer than 1 in 2,000 people. However, there are more than 6,000 rare diseases known. As a result, a significant proportion of the population are affected by a rare disease (thought to be around 30 million people in Europe and around 25-30 million in the USA). In addition, it is estimated that around 80% of rare diseases are genetic diseases and so many affect new-born and young children, with some symptoms being severely debilitating.

The population available to recruit for clinical trials and the market size for the treatment of each rare disease are very small. As such, the development of treatments for rare diseases more difficult and less attractive than other indications for pharmaceutical companies. However, the Orphan Drugs Act of 1983 in the US sought to provide additional incentives for the development of treatments of rare or orphan diseases. Incidentally, one of the reported influences in bringing the US Orphan Drugs Act into effect was the popular US television series, "Quincy, M. E.," which aired an episode in 1981 addressing the challenges facing a Tourette's patient, and another episode the following year, about myoclonus.

Similar legislation to the Orphan Drugs Act in the US was enacted in Europe in 1999 with EU Regulation (EC) No 141/2000. One of the most powerful incentives granted for orphan drugs by the European Medicines Agency (EMA) is ten year market exclusivity in the orphan indication for any drug with orphan drug status.

In more recent years, rare diseases have come into the focus of the public through campaigns, such as the "Ice Bucket Challenge" which raised the awareness of ALS (as well as in the order of $115 million to help fund ALS research). The UK government published its Strategy for Rare Diseases in 2013. The main focus of the strategy was to commit to taking action in five areas:

  • empowering those affected by rare diseases
  • identifying and preventing rare diseases
  • diagnosis and early intervention
  • coordination of care; and
  • the role of research.

The UK Government published their progress report here in 2018. The progress report acknowledges the large role that developments in genomics have had in the area of rare diseases, including the 100,000 Genomes Project.

The legislative changes and focus on rare disease have had a significant impact on the orphan drug market. As an indicator, the number of patent application families filed relating to the treatment of motor neurone disease (ALS), acute myeloid leukaemia (AML), cystic fibrosis, multiple myeloma or muscular dystrophy has risen from around 200 in 1997 to over 1200 in 2017.

This trend appears to translate into a marked increase in the number of medicinal products entering the market. A 2017 study suggests that 104 orphan medicines were approved by the EMA between 2000 and 2013 compared to 374 non-orphan medicines. Of the 55 medicinal products under evaluation at the EMA at the end of 2018 (excluding generics and biosimilars), 20 of these products are orphan medicinal products.

The success of Celgene's Revlimid (lenalodomide) may have contributed to their recent acquisition by Bristol Myer-Squibb. Big name pharmaceutical companies have had success with rare disease drug approval, but several small niche drug developers have made a name in the rare disease field. For example, Alexion Pharmaceuticals' Soliris (eculizumab) is one of the top rare disease therapies and the US FDA recently approving Alexion's follow-up PNH treatment, Ultomiris, which promises to reduce dosing frequency in PNH patients. Vertex Pharmaceuticals is a market leader in the treatment of cystic fibrosis with three FDA approved drugs on the market, and more in the pipeline (along with a significant proportion of patent applications filed in the area of cystic fibrosis). Roche announced this week that it would buy Spark Therapeutics for $4.8bn. Spark currently have approval for Luxturna for the treatment of the rare inherited retinal disease caused by mutations in both copies of the RPE65 gene. Treatment with Luxturna is reported to cost an eye-watering $850,000 in the US, making it the most expensive drug on the market.

It is not surprising then that the forecast for the worldwide orphan drug sale market will be $262 billion by 2024. The same report forecasts sales for pipeline orphan drugs will account for over a third of total R&D pipeline sales through to 2024. Inevitably, the number of patent application filings in the area of orphan drugs is likely to increase in the next few years.

An area of concern with respect to orphan drugs (and more generally in the pharmaceutical industry) is the pricing of the drugs. With such a small population affected by a particular rare disease, the cost for the treatment for rare diseases can be significantly higher than more common disease treatments. The price of treatment for some approved orphan drugs run in excess of $400,000.

This cost factor may be a reason why the number of approved drugs based on known substances at the EMA between 2000 and 2013 was proportionally higher for orphan drugs than non-orphan drugs. It is possible in Europe to get patent protection for a known drug if it can be plausibly shown that it will treat another indication. The protection afforded by such "second medical use" claims is limited to the new indication and evidence (e.g. assay data) must be provided at the time of filing the new patent application.

As with any product, those looking to develop and bring to market rare disease treatments need to bear in mind their freedom to operate. It is possible in patent law for a product to be new and inventive (and therefore patented) but also to fall within someone else's patent rights. It is important to search for earlier patent rights before entering the market to avoid a risk of litigation.

Traditional treatment areas, such as cancer, cardiovascular disease and infectious diseases, will continue to dominate the drug development market. However, it is encouraging for patient outcomes that there is recognition and drug development in the rare disease area. As with conventional drug development, patent protection for treatments of rare diseases will provide crucial incentive for companies to develop such treatments and bring them to market.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions